A Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD) Trial of Multiple Ascending Fixed Doses of SAM-531 in Subjects With Mild to Moderate Alzheimer's Disease.

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD) Trial of Multiple Ascending Fixed Doses of SAM-531 in Subjects With Mild to Moderate Alzheimer's Disease.

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Jan 2010

At a glance

  • Drugs Cerlapirdine (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions
  • Sponsors Wyeth
  • Most Recent Events

    • 22 Jun 2008 Patient numbers amended from 78 to 72 as reported by ClinicalTrials.gov.
    • 22 Jun 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 27 Dec 2007 Status change from initiated to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top